Feb 17, 2026 08:00AM
Feb 5, 2026 08:05AM
Feb 5, 2026 08:00AM
Jan 13, 2026 07:20AM
Jan 5, 2026 08:03AM
Jan 5, 2026 08:00AM
Dec 18, 2025 07:30AM Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
Dec 17, 2025 04:03PM
Nov 25, 2025 08:02AM
Nov 25, 2025 08:00AM
Nov 21, 2025 07:30AM
Nov 21, 2025 07:30AM
Nov 12, 2025 08:01AM
Nov 12, 2025 08:00AM Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
Oct 23, 2025 07:30AM
Oct 23, 2025 07:30AM
Oct 21, 2025 07:32AM
Oct 21, 2025 07:30AM
Oct 14, 2025 08:02AM
Oct 14, 2025 08:00AM
Oct 9, 2025 07:31AM Telomir Pharmaceuticals reports cancer drug shows effects on breast cancer cells
Oct 9, 2025 07:30AM
Oct 7, 2025 07:30AM
Oct 7, 2025 07:30AM
Oct 6, 2025 04:05PM
Sep 18, 2025 08:00AM
Sep 9, 2025 08:13AM
Sep 9, 2025 08:00AM Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapa
Aug 28, 2025 08:00AM
Aug 28, 2025 08:00AM
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM
Jul 24, 2025 08:01AM
Jul 24, 2025 08:00AM
Jul 18, 2025 08:00AM Telomir shows drug reverses gene silencing in prostate cancer study
Jul 18, 2025 08:00AM
Jun 18, 2025 09:15AM
Jun 18, 2025 09:15AM
Jun 11, 2025 09:42AM
Jun 11, 2025 09:30AM
Jun 5, 2025 08:30AM
Jun 2, 2025 08:30AM Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
May 29, 2025 08:43AM
May 29, 2025 08:30AM
May 21, 2025 09:03AM
May 21, 2025 09:00AM
May 15, 2025 08:04AM
May 15, 2025 08:00AM
May 7, 2025 08:04AM Telomir Pharmaceuticals (TELO) Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
May 7, 2025 08:00AM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All